💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Vemurafenib

CHEMBL1229517 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
489.9 g/mol
LogP
5.0
Phase
4

This targeted therapy is used to treat melanoma that has spread to other parts of the body and carries a specific mutation in the BRAF gene (V600E). It works by blocking the mutated BRAF protein that tells cancer cells to grow uncontrollably. Resistance often develops within months of starting treatment, so it is sometimes combined with MEK inhibitors to prolong effectiveness.

आणविक भार

489.9000 g/mol

LogP

5.00

TPSA

100.00 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अग्नाशय कैंसर ओवेरियन कैंसर कोलोरेक्टल कैंसर थायरॉइड कैंसर नॉन-स्मॉल सेल लंग कैंसर प्रोस्टेट कैंसर मूत्राशय कैंसर मेलानोमा लिम्फोमा ल्यूकेमिया स्तन कैंसर

क्रिया का तंत्र

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(-c4ccc(Cl)cc4)cc23)c1F

                

                

                
                

                    
InChI

                    
InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H18ClF2N3O3S

                    

                    
                    

                        
HBD / HBA

                        
2 / 7

                    

                    
                    

                        
घूर्णनीय बंधन

                        
7

                    

                    
                    
                    

                        
भारी परमाणु

                        
33

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
This targeted therapy is used to treat melanoma that has spread to other parts of the body and carries a specific mutation in the BRAF gene (V600E). It works by blocking the mutated BRAF protein that tells cancer cells to grow uncontrollably. Resistance often develops within months of starting treatment, so it is sometimes combined with MEK inhibitors to prolong effectiveness.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits BRAF kinase, a key component of the RAS/MAPK signaling pathway, blocking constitutive activation that drives cancer cell proliferation in tumors harboring BRAF mutations.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Vemurafenib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1229517.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 42611257.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.